Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
genetic diseases
Biotech
Genentech drug fails rare disease study, raising obesity questions
Genentech will not push anti-myostatin antibody emugrobart into phase 3 for two muscle-wasting diseases after it failed to improve muscle growth.
Darren Incorvaia
Mar 20, 2026 2:11pm
Alltrna CEO departs amid 35% layoff round
Mar 6, 2026 8:30pm
Atrium arises from Avidity buyout with $270M, preclinical assets
Feb 27, 2026 11:05am
Senate hearing takes aim at FDA's rare disease review process
Feb 26, 2026 3:50pm
Boehringer axes gene therapy after seeing cystic fibrosis data
Feb 17, 2026 1:12pm
GSK won't pick up Wave's genetic disease RNA editor
Feb 2, 2026 11:14am
